HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

eleclazine

inhibits cardiac late sodium current

Also Known As:

GS-6615

Networked: 7 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azepines: 11
    - Oxazepines: 5
      - eleclazine: 7

Experts

1.	Belardinelli, Luiz: 6 articles (01/2018 - 01/2016)
2.	Nearing, Bruce D: 4 articles (03/2017 - 01/2016)
3.	Verrier, Richard L: 4 articles (03/2017 - 01/2016)
4.	Rajamani, Sridharan: 4 articles (01/2017 - 01/2016)
5.	Kahlig, Kristopher M: 3 articles (01/2018 - 01/2016)
6.	El-Bizri, Nesrine: 2 articles (01/2018 - 11/2016)
7.	Fuller, Henrique: 2 articles (01/2016 - 01/2016)
8.	Justo, Fernanda: 2 articles (01/2016 - 01/2016)
9.	Hirakawa, Ryoko: 1 article (01/2018)
10.	Krause, Michael: 1 article (01/2018)

Related Diseases

1.	Atrial Fibrillation 01/01/2016 - "Eleclazine, a new selective cardiac late sodium current inhibitor, confers concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in an intact porcine model." 01/01/2016 - "The purpose of this study was to investigate whether selective inhibition of the cardiac late sodium current (INa) with eleclazine decreases susceptibility to ischemia-induced atrial fibrillation (AF) and atrial and ventricular repolarization abnormalities before and after epinephrine infusion. " 01/01/2016 - "Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation."
2.	Ischemia 01/01/2016 - "Eleclazine reduced the ischemia-induced surge in TWA by 81% (P = .007), T-wave heterogeneity by 23% (P = .035), and Tpeak-Tend by 28% (P = .014), suppressed the ischemia-induced surge in atrial TWAa by 64% (P = .002), and reduced the ischemia-induced fall in AF threshold to 20%. " 01/01/2016 - "Selective inhibition of cardiac late INa with eleclazine confers dual protection against vulnerability to ischemia-induced AF and reduces atrial and ventricular repolarization abnormalities before and during adrenergic stimulation without negative inotropic effects." 01/01/2016 - "The purpose of this study was to investigate whether selective inhibition of the cardiac late sodium current (INa) with eleclazine decreases susceptibility to ischemia-induced atrial fibrillation (AF) and atrial and ventricular repolarization abnormalities before and after epinephrine infusion. " 01/01/2016 - "Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation."
3.	Ventricular Tachycardia 01/01/2017 - "The prolongations caused by Bay K 8644 and frequent episodes of ventricular tachycardias, both in absence and presence of ATX-II, were significantly attenuated or abolished by late I Na inhibitors TTX and eleclazine. " 01/01/2017 - "Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model."
4.	Premature Cardiac Complexes (Extrasystoles) 01/01/2016 - "We tested whether late INa inhibition by eleclazine confers protection against atrial premature beats (APBs) and AF. " 01/01/2017 - "Eleclazine reduced the incidence of epinephrine-induced ventricular premature beats and couplets by 51% (from 31.3 ± 1.91 to 15.2 ± 5.08 episodes; P = .038) and the incidence of 3- to 7-beat VT by 56% (from 10.8 ± 3.45 to 4.7 ± 3.12 episodes; P = .004). " 01/01/2016 - "Eleclazine, a new selective cardiac late sodium current inhibitor, confers concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in an intact porcine model."
5.	Brugada Syndrome 01/01/2018 - "The goals of this study were to investigate the inhibition of late INa by eleclazine using a sample of long QT syndrome type 3 (LQT3) and overlap LQT3/Brugada syndrome mutant channels; to compare the apparent binding rates for eleclazine with those for other class 1 antiarrhythmic agents; and to investigate the binding site. " 01/01/2018 - "At predicted therapeutic concentrations, eleclazine and ranolazine inhibited peak INa to a similar degree as assessed with 4 overlap LQT3/Brugada syndrome mutations. "

Related Drugs and Biologics

1.	Sodium
2.	Adrenergic Agents (Adrenergic Drugs)
3.	Flecainide (Tambocor)
4.	Catecholamines
5.	Epinephrine (Adrenaline)
6.	Methyl ester 1,4- dihydro- 2,6- dimethyl- 5- nitro- 4- (2- (trifluoromethyl)phenyl)- 3-Pyridinecarboxylic acid
7.	Amiodarone (Amiodarona)
8.	Ranolazine